Overall, targeting mutations in tyrosine kinases has been a fruitful therapeutic strategy: BCR-ABL inhibitors have transformed treatment of CML, and both mAbs and TKIs are standard-of-care for EGFR-mutant NSCLC and HER2-positive BC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.